## Common ground
Both options refer to the same active pharmaceutical ingredient, bupropion hydrochloride, used for treating depression and smoking cessation.
## Options at a glance
**2922.39 – Bulk form**
- **Defining trait:** Sold as raw, unprocessed powder or granules, not yet formulated into a final medicine.
- **Typical examples:** Pharmaceutical intermediates, bulk API for manufacturing.
- **Best fit when:** The product is intended for further processing by another manufacturer.
**3004.90 – Extended release tablets**
- **Defining trait:** Formulated as a finished dosage form with controlled-release technology for prolonged effect.
- **Typical examples:** Wellbutrin XL, sustained-release pills taken once daily.
- **Best fit when:** The product is ready for patient use and delivered in a specific, regulated tablet form.
## Key differences
| Feature | 2922.39 (Bulk) | 3004.90 (Tablets) |
|-----------------------|----------------------|----------------------------|
| Form | Raw powder/granules | Finished tablet |
| Release type | Not specified | Extended release |
| Use | Manufacturing input | Direct patient use |
| Regulatory status | API | Finished drug product |
## How to choose
- Is the product sold as raw material for further processing? → 2922.39
- Is it a tablet designed for once-daily dosing with controlled release? → 3004.90
## Overlaps & pitfalls
A product could technically be both if it’s bulk API *and* used in extended-release tablets, but the HS Code depends on the actual form at trade. The key is whether it's **in bulk** (2922.39) or **in final dosage form** (3004.90). If unclear, prioritize the product’s **main function**: API vs. medicine